Why the study?
Do different classes of antihypertensive drugs have differing effects on cardiovascular risk factors and subsequent cardiac events?
Do different classes of antihypertensive drugs have differing effects on cardiovascular risk factors and subsequent cardiac events?
Antihypertensive drug classes differ in their metabolic and structural effects, which may influence their ability to reduce cardiovascular events and warrants further prospective investigation.
Answers are grounded in this paper and cite their sources.
Metabolic differences should not alter antihypertensive selection; leaves open whether they explain inconsistent outcomes in prospective trials.
The lack of success of antihypertensive drug therapy in decreasing cardiovascular events has caused close examination of the influence of antihypertensive drugs on cardiac risk factors. Striking differences exist in the pharmacological profiles of antihypertensive drug classes and subclasses as well as in the influences of the drugs on electrolyte, lipid, and glucose metabolism. Differences also exist in the effects of the drugs on left ventricular hypertrophy. These differences in the effects of antihypertensive drugs on cardiac risk factors may assist in explaining the lack of a favorable effect on cardiovascular events in previous clinical trials. However, prospective trials are necessary to demonstrate that treatment of hypertension with drugs that have a more favorable effect on cardiac risk factors will reduce cardiac events (i.e., myocardial infarction, heart failure, and sudden death).
No takes yet. Share an insight, caveat, or question.
Thomas D. Giles (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: